NCT05765513View on ClinicalTrials.gov

HA35 Treatment the Gingival Discomfort as Well as Gingival Redness and Bleeding of Patients With Periodontitis

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

July 20, 2023

Study Completion Date

August 11, 2023

Conditions
Periodontitis
Interventions
DRUG

HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)

The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.

Trial Locations (1)

Unknown

Huinuode Biotechnology Co., Ltd., Qingdao

All Listed Sponsors
lead

Dove Medical Press Ltd

NETWORK